• Amgen (NasdaqGS:AMGN) has been selected by the FDA as one of only two companies to run proof of concept trials under the new real time clinical trials initiative.
• The program is designed to enable continuous clinical development with real time data sharing between companies and the FDA.
• The collaboration focuses on reshaping how trials are designed, monitored, and adapted during the development of new therapies.

Amgen is a large biotechnology company with a broad portfolio of therapies and a long history in clinical development. The FDA’s real time clinical trials initiative fits with a wider move across healthcare towards data driven decision making and closer digital integration between regulators and companies. For investors, this places Amgen at the center of a regulatory experiment that could influence how drug candidates move through development.

The pilot could affect how quickly Amgen gains insight into efficacy and safety signals across its pipeline, which may matter for R&D planning and capital allocation. If real time clinical trials become more widely adopted, early participants such as Amgen could be better prepared for new expectations around data infrastructure, trial design, and ongoing regulatory interaction.

Stay updated on the most important news stories for Amgen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amgen.

Investor Checklist

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$329.59, Amgen trades about 6.6% below the average analyst target of US$353.07, with a wide target range between US$200 and US$432.
• ✅ Simply Wall St Valuation: Amgen is assessed as trading about 50.8% below estimated fair value, flagging a valuation gap to monitor.
• ❌ Recent Momentum: The stock shows a 30 day return of about 5.3% decline, so the news is landing after a softer short term stretch.

There is only one way to know the right time to buy, sell or hold Amgen. Head to the Simply Wall St company report for the latest analysis of Amgen's Fair Value.

Key Considerations

• 📊 Participation in the real time clinical trials program may influence how efficiently Amgen runs trials, which could matter for how its R&D spending converts into approved therapies.
• 📊 Watch how regulators and Amgen report on trial timelines, data quality and any changes to development costs as the RTCT pilot progresses.
• ⚠️ Simply Wall St highlights that Amgen's debt is not well covered by operating cash flow, so investors may want to see that new trial processes do not add sustained funding pressure.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Amgen analysis. Alternatively, you can check out the community page for Amgen to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.